NASDAQ: SNCEScience 37 Holdings Inc Stock
$0.28-0.02 (-6.67%)
Updated Mar 24, 2023
SNCE Price
$0.28
Fair Value Price
$1.21
Market Cap
$32.80M
52 Week Low
$0.19
52 Week High
$5.98
P/E
-0.64x
P/B
0.34x
P/S
0.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$70.15M
Earnings
-$50.99M
Gross Margin
22.6%
Operating Margin
-72.82%
Profit Margin
-72.7%
Debt to Equity
0.3
Operating Cash Flow
-$75M
Beta
0.92
Next Earnings
May 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A
SNCE Overview
Science 37 Holdings, Inc. provides technology-based solutions to enable agile clinical trials and decentralized approaches. Its platform enables modern and digital approaches to clinical research by bringing together all parties, including the patient and trial investigators, nurses, coordinators, and sponsors to power workflows, centralize evidence generation, and harmonize data. Its platform also provides specialized networks of patient communities, telemedicine investigators, mobile nurses, remote coordinators, and connected devices for orchestrating agile clinical trials; and extensive configuration to support virtually any phase of clinical study and any indication. In addition, the company licenses its proprietary hosted technology platform to various life science institutions. It serves large and mid-sized pharmaceutical companies, contract research organizations, academic institutions, and biotech companies. Science 37 Holdings, Inc. was founded in 2014 and is based in Research Triangle Park, North Carolina.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SNCE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SNCE ($0.28) is undervalued by 76.77% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SNCE ($0.28) is significantly undervalued by 76.77% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SNCE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SNCE due diligence checks available for Premium users.
Be the first to know about important SNCE news, forecast changes, insider trades & much more!
SNCE News
Valuation
SNCE fair value
Fair Value of SNCE stock based on Discounted Cash Flow (DCF)
Price
$0.28
Fair Value
$1.21
Undervalued by
76.85%
SNCE ($0.28) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SNCE ($0.28) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SNCE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SNCE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.64x
Industry
3.36x
Market
21.37x
SNCE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.34x
Industry
3.47x
SNCE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SNCE's financial health
Profit margin
Revenue
$15.9M
Net Income
-$66.5M
Profit Margin
-417.4%
SNCE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SNCE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$126.4M
Liabilities
$29.1M
Debt to equity
0.3
SNCE's short-term assets ($126.20M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SNCE's short-term assets ($126.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SNCE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.1M
Investing
-$7.1M
Financing
-$62.0k
SNCE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SNCE vs Health Information Service Stocks
Science 37 Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.